Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.

Abstract: Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a cassette unit housing cavity and a needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. The plunger slaving part is arranged such that when a drive load is applied to its rear drive-receiving face to bring the front plunger-contacting face into contact with the plunger the drive load is evenly transmitted. The circumferential wall is provided with slide restrictors that restrict frictional sliding movement thereof in relation to the inner wall of the barrel.

Abstract: There is provided a cassette unit suitable for use with an auto-injector. The cassette unit comprises a cassette unit housing and a removable cap that in a capping position fits over and thereby, acts to close off, a needle projection aperture of the housing. The cassette unit housing has one or more first engagement features arranged for reversibly engaging one or more second engagement features of the removable cap for reversible lock engagement of the removable cap to the housing; and a shuttle lock control defining one or more blocking elements for selectively blocking movement of said first engagement features relative to said second engagement features. The shuttle lock control is axially movable relative to the cassette unit housing between a first ‘cassette unused’ position; a second ‘cassette unlocked’ position; and after replacement of the removable cap, a third ‘cassette used’ position, locating intermediate the first and second positions.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract: A humanized agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.